Intelligence · Decide
Decision-grade intelligence across global cannabis.
Cannamonitor Decide is the market-intelligence platform for cannabis — every country, company, deal, filing and trial connected in one analyst-curated graph, so you can decide, not just read.
What is Decide
The whole cannabis market, in one place — and already connected.
Today you assemble it yourself: ten browser tabs, a paywalled filing, a half-translated regulator PDF, a stale news alert — and still no clear view. Decide replaces that. It’s a market-intelligence platform that pulls every country, company, deal, filing and trial into one analyst-curated graph, so the context is already built when you arrive.
The old way
11 browser tabs open
Paywalled filing 🔒
Regulator PDF — in German
News alert, 3 days stale
…still no clear view
→
With Decide
One analyst-curated graph.
Every country, company, deal, filing and trial — already connected. The context is built before you arrive.
CountriesCompaniesNewsRegulatoryEarningsM&ATrialsMarket data
The connected graph
One graph, not ten spreadsheets.
Countries and Companies are the dual core — every other dataset hangs off them. Open any company and its country context, market data, earnings, deals, news, regulation and trials are already linked.
Countries and Companies are the dual core — every dataset hangs off them. Click any node to see what it adds.
What’s inside
Twelve connected modules. One subscription.
Not a feed — a relational system. Here’s what each module gives you.
Countries →
the market-entry OS
- Assess any target market end-to-end: regulation, demand, supply, competition.
- Decision-grade intel you can act on — size a market or justify a pivot.
- Linked to every company, deal and dataset in that jurisdiction.
Companies →
the same OS, per operator — 1,000+ profiles
- One page per company: financials, news, deals, trials, licences.
- The value is the integration — everything about a company already joined up.
- Benchmark any operator against its market and peers.
News →
read it all without leaving
- Vetted sources only — signal, not noise.
- Past the paywalls, with analyst summaries so you grasp it fast.
- Everything lives in the platform — no tab-hopping to read the story.
Regulatory →
a living layer
- Updates as situations develop, not a static archive.
- Sentiment / political-risk scoring — see what’s at stake per market at a glance.
- Tied to the country and the companies it affects.
Earnings & Financials →
comparable, not just collected
- Standardised (currency, units, definitions) so figures compare.
- Private-company signals included, not only listed names.
- Tracked over time — margins and trajectory, not a single quarter.
M&A & Funding →
every deal, with the analysis
- 550+ deals, normalised to USD and source-linked.
- Consideration split (upfront / earn-out / equity) and multiples where disclosed.
- Each deal connected to buyer, target and market.
Investors →
who’s backing the market
- The capital behind the deals — funds, strategics, lenders.
- Linked to their portfolio companies and deals.
- Spot active and emerging backers by market.
Market data →
structured quant datasets
- Cleaned, structured, analysed datasets from official and aggregated sources.
- Illuminates trade, products and company performance — the hard numbers.
- Cross-cuts the graph: linked to both countries and companies.
Clinical trials →
evidence, standardised
- Standardised categories — find evidence by condition, substance and population.
- Readouts and status tracked over time.
- Matched to the company and product behind each trial.
Science & investigational products →
the R&D pipeline
- The research and pipeline behind the market, on the same taxonomy as trials.
- Find investigational products by indication and mechanism.
- Connected to companies, trials and regulation.
Analyst datapacks →
curated deep-dives
- Topic-level deep-dives built by analysts (a market, a theme, a question).
- The “so what”, packaged — not raw data you have to work.
- New packs added continuously.
Content hub →
the brief, expanded
- Full, expanded recaps of the monthly brief, webinars and podcasts.
- The underlying data attached to every piece.
- One home for the narrative layer.
See it work
Follow one decision, end to end.
A single thread through the graph — here, Germany.
Regulation · 9 Jun 2026
Germany authorises Exilby
A new cannabinoid medicine — the market opens.
→
Company
Vertanical
The developer behind it — and its pipeline.
→
Country
Germany
Europe’s largest medical market — the demand and rules it lands in.
→
Market data
Telemedicine ≈ 8.56M monthly visits
How big the channel actually is.
→
Insight
“Cannabinoids come of age”
The analyst read — what it means for operators and investors.
Every one of these was one click from the last — in Decide.
Who uses Decide
Three jobs teams hire Decide to do.
Not a generic “who it’s for” — the actual questions you’re trying to answer.
Job 1 — Investment & Corporate Strategy
“Where should we allocate capital?”
Tasks
Deal underwriting · portfolio monitoring · board reporting · market-share analysis · strategic planning · growth-opportunity assessment.
For
Investors · corporate development · CEOs · boards
Job 2 — Market Entry & Commercial Development
“Who should we work with, and where should we expand?”
Tasks
Market sizing · entry assessment · account research · partner due diligence · target identification · expansion planning.
For
Business development · commercial · partnerships · international expansion
Job 3 — Regulatory & Supply-Chain Intelligence
“How does the market actually operate?”
Tasks
Licence tracking · import/export monitoring · supplier mapping · GMP intelligence · regulatory monitoring · supply-chain analysis.
For
Operations · procurement · regulatory affairs · strategy
Decision-grade
The headline is not the decision.
Anyone can repeat a press release. Decide’s analysts tell you what the number actually means — because the headline and the decision often point in opposite directions.
This is what “nothing enters without human review” buys you.
How we build it
We don’t aggregate information. We curate evidence, impose structure, preserve history and add context.
Four principles separate Decide from a news feed, a Google alert or an AI scraper.
1Source discipline
evidence over hearsay
Most cannabis intelligence starts with headlines. We start with evidence.
- Prioritise primary sources: filings, regulatory documents, court records, financial reports, customs data and official statistics.
- Trace every claim to its origin — not media interpretation or industry hearsay.
- Preserve the underlying documents so you can verify our conclusions yourself.
2Structured intelligence
ontology over noise
Turn fragmented information into decision-ready knowledge.
- Cannabis-specific ontologies: companies, products, facilities, licences, markets, regulations and transactions.
- Standardise diverse inputs into one framework — compare across jurisdictions and time.
- Connect related entities and events so information is read in context, not isolation.
3Longitudinal analysis
the movie, not the snapshot
Markets evolve through sequences, not isolated events.
- Track developments over time instead of treating announcements as standalone news.
- Keep change histories so trends, patterns and strategic direction surface.
- Show what changed, what held constant, and why it matters.
4Contextualisation
information becomes intelligence
A number only means something in context.
- Connect each development to the wider market, regulatory and competitive picture.
- Separate signal from noise by judging materiality and likely impact.
- Explain why it matters for investors, operators and strategists — where editorial judgement lives.
Proof
Coverage that compounds every week.
120+
countries
1,000+
companies
9,500+
news items
1,300+
clinical trials
550+
deals
Drawn from 420+ monitored sources and 780+ primary-source documents · trusted by operators, investors and regulators · updated every week
Objections
Common questions.
With AI, you do the work: chasing credible sources, checking they’re current, reconciling numbers that clash, then cleaning and formatting it — every time. Decide hands you that finished: vetted, reconciled to one schema, traced to the original filing, ready to query. You’re saving the hours AI leaves on your desk.
News says a thing happened. Decide connects it to the company, country, filing and trial — and tells you what it means. A graph, not a feed.
Standardised units and currencies, contradictions reconciled (not averaged away), the original source one click away, and analyst context on what it means.
Updated continuously, with change logs showing what moved and when — e.g. +4 datasets, +16 dashboards, +23 company profiles and 196 news stories in the week to 19 Jun 2026.
Essentials keeps one professional aware of the market. Decide is a company-grade tool providing decision-grade intelligene — more data modules, all fully linked.
out €118/month, or under €4 a day, for decision-grade intelligence. One avoided mistake, one faster diligence or one sharper board pack pays for the year — and Decide replaces several single-purpose subscriptions plus the analyst hours spent stitching them together, for less than the cost of an afternoon’s research.
120+ countries, deepest in internationally-exposed, demand markets like Canada, Germany, UK and Australia. If your market is light, tell us — coverage expands every week.
Pricing
One plan. The whole graph.
No tiers to decode — Decide is everything. Compare all plans on the Plans page.
Decide
€1,420/year
Billed annually · about €118/month · under €4/day
The full graph, every module, decision-grade data.
Start now →
Self-serve checkout · annual plan